European Commission approves license extension for Kaftrio (ivacaftor/tezacaftor/elexacaftor) in cystic fibrosis

Its expanded approval, which means it is now available in the EU for the treatment of all cystic fibrosis patients aged ≥12 years who have at least one F508del mutation in the CFTR gene, is based on three Phase III studies evaluating it in a range of mutations.

Source:

PharmaTimes